WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130338
CAS#: 1956368-15-2
Description: KB05, also known as N-(4-Bromophenyl)-N-phenylacrylamide, is a ‘Scout’ fragment and was found to display broad cysteine reactivity in the human proteome, being able to capture reactive cysteine residues of the E3 ubiquitin ligase pool, providing a tool for ligand discovery and for use in PROTAC development.
Hodoodo Cat#: H130338
Name: KB05
CAS#: 1956368-15-2
Chemical Formula: C15H12BrNO
Exact Mass: 301.01
Molecular Weight: 302.170
Elemental Analysis: C, 59.62; H, 4.00; Br, 26.44; N, 4.64; O, 5.29
Synonym: KB05; N-(4-Bromophenyl)-N-phenylacrylamide
IUPAC/Chemical Name: N-(4-bromophenyl)-N-phenylacrylamide
InChi Key: WFQQVUPOAKOTGT-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H12BrNO/c1-2-15(18)17(13-6-4-3-5-7-13)14-10-8-12(16)9-11-14/h2-11H,1H2
SMILES Code: C=CC(N(C1=CC=C(Br)C=C1)C2=CC=CC=C2)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 302.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Qin L, Dai H, Wang J. Key Considerations in Targeted Protein Degradation Drug Discovery and Development. Front Chem. 2022 Aug 1;10:934337. doi: 10.3389/fchem.2022.934337. PMID: 35978859; PMCID: PMC9376879.
2. Crowley VM, Thielert M, Cravatt BF. Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization. ACS Cent Sci. 2021 Apr 28;7(4):613-623. doi: 10.1021/acscentsci.0c01336. Epub 2021 Apr 5. PMID: 34056091; PMCID: PMC8155467.
3. Scholes NS, Mayor-Ruiz C, Winter GE. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches. Cell Chem Biol. 2021 Jul 15;28(7):1048-1060. doi: 10.1016/j.chembiol.2021.03.007. Epub 2021 Apr 2. PMID: 33811812.